| Ytd | 56.44% | |
| 1y | -14.70% |
| Open | 11.76 | Prev Close | 11.34 | Low | 11.48 | High | 13.55 | Mkt Cap | 875.42M |
| Vol | 4.52M | Avg Vol | 1.80M | EPS | -5.80 | P/E | N/A | Forward P/E | -5.17 |
| Beta | 1.79 | Short Ratio | 6.35 | Inst. Own | 73.73% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 8.48 | 200-d Avg | 8.41 | 1yr Est | 7.00 |
Glaukos reports positive Phase 4 results for its iDose TR therapy, demonstrating superior efficacy o
Ginkgo Bioworks Inc. (NYSE:DNA) is strengthening national biotechnology infrastructure by granting r
Ginkgo Bioworks offers remote autonomous lab access to NSF X-Labs and integrates Araceli imaging int
U.S. stocks rose Friday; Humana jumped 12.3% after improved 2027 Medicare Advantage ratings and reaf
/PRNewswire/ -- Araceli Biosciences und Ginkgo Bioworks (NYSE: DNA) gaben heute die Integration des
Ginkgo Bioworks (NYSE:DNA) today announced that it will provide in-kind access to its autonomous lab
BOSTON--(BUSINESS WIRE)--Ginkgo Bioworks (NYSE: DNA) today announced that it will provide in-kind ac
/PRNewswire/ -- Araceli Biosciences y Ginkgo Bioworks (NYSE: DNA) han dado a conocer hoy la integrac
The Endeavor, the world's fastest high-content imaging system, brings cellular imaging with real
The Endeavor® adds the fastest high-content cellular data generation to Ginkgo's around-the-clock re
Ginkgo Bioworks Holdings, Inc. (DNA) closed the most recent trading day at $11.47, moving 7.57% from
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA - Get Free Report) reached a new 52-week high on Tuesday.
U.S. stocks rose; Apogee surged 10% on strong results and raised guidance, while Option Care, Ginkgo
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA - Get Free Report) saw unusually-strong trading volume on
Ginkgo Bioworks and Eli Lilly announced a partnership last month focused on AI drug discovery. The s
In the closing of the recent trading day, Ginkgo Bioworks Holdings, Inc. (DNA) stood at $12.5, denot
Nasdaq fell 150+ points, while Everpure jumped 14% after unveiling growth plans and a FY2028 outlook
Agreement would expand the companies' genetic testing collaboration beyond ophthalmology to a select
In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $8.58, marking a -8.43
Ginkgo Bioworks (DNA) was a big mover last session on higher-than-average trading volume. The latest
Ginkgo Bioworks Holdings, Inc. (DNA) concluded the recent trading session at $7.06, signifying a +1%
BOSTON--(BUSINESS WIRE)--Ginkgo Bioworks (NYSE: DNA) today announced that its Ginkgo Datapoints offe
BOSTON--(BUSINESS WIRE)--Ginkgo Bioworks (NYSE: DNA) today announced that it has been awarded a subc
BTIG analyst Mark Massaro reiterates Ginkgo Bioworks Holdings (NYSE:DNA) with a Sell and maintain
- Strengthened balance sheet with $1.8 million cash from new convertible debt in Q2 and additional $
Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting str
Prada Group CEO Andrea Guerra speaks to CNBC's Charlotte Reed about global luxury consumers, keeping
Ginkgo Bioworks NYSE: DNA reported second-quarter 2026 revenue of $20 million, down 48% from the yea
TD Cowen analyst Brendan Smith downgrades Ginkgo Bioworks Holdings (NYSE:DNA) from Buy to Hold an
Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2026 Earnings Call Transcript
https://www.cdc.gov/ebola/situation-summary/index.html
ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transf
BTIG analyst Mark Massaro maintains Ginkgo Bioworks Holdings (NYSE:DNA) with a Sell and lowers th
Elon Musk tweeted about wanting Jurassic Park in real life. Companies aren't bringing back dinos
Ginkgo Bioworks (NYSE: DNA) today announced the official launch of Ginkgo Cloud Lab. This new interf
Ginkgo Bioworks stock drops after earnings miss, lower sales, and shift to autonomous labs and robot
Ginkgo today announced it has reached an agreement to sell the Company's biosecurity business to
Ginkgo Bioworks Holdings (NYSE:DNA) reported quarterly losses of $(1.41) per share which missed the
Ginkgo Bioworks (NYSE:DNA) today announced it has demonstrated, in collaboration with OpenAI, an AI
TD Cowen analyst Brendan Smith maintains Ginkgo Bioworks Holdings (NYSE:DNA) with a Buy and lower
Ginkgo Bioworks shares are trading higher Monday afternoon, up over 8%, following the announcement o
ProteoNic BV, a leading provider of premium vector technology for biopharmaceutical and viral vector